PHARMALITA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,318,899 | 4,199,841 | 3,926,897 | 4,304,553 | 5,392,785 | 5,667,788 | 5,683,998 | 5,837,681 |
| Profit before tax | 167,479 | 150,463 | 113,030 | 333,122 | 584,721 | 388,371 | 306,361 | 348,881 |
| Net profit | 159,091 | 141,448 | 75,103 | 288,770 | 495,667 | 324,974 | 249,241 | 278,830 |
| Equity | -78,737 | 62,711 | 137,814 | 426,584 | 922,251 | 1,247,225 | 1,496,466 | 1,830,125 |
| Liabilities | 2,821,623 | 2,726,409 | 2,766,452 | 2,231,772 | 2,038,201 | 1,951,746 | 2,267,745 | 2,082,977 |
| Non-current assets | 1 | 67,549 | 145,148 | 106,373 | 118,810 | 86,911 | 72,390 | 3,079 |
| Current assets | 2,742,885 | 2,726,090 | 2,763,176 | 2,557,363 | 2,846,984 | 3,113,367 | 3,693,726 | 3,906,389 |
| Total assets | 2,742,886 | 2,793,639 | 2,908,324 | 2,663,736 | 2,965,794 | 3,200,278 | 3,766,116 | 3,909,468 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 440,189 | 406,329 | 522,830 |
| Social insurance contributions | - | - | - | - | - | 21,431 | 18,852 | 140,631 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +22.4% | +26.5% | -6.5% | +9.6% | +25.3% | +5.1% | +0.3% | +2.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.8% | 5.1% | 2.6% | 10.8% | 16.7% | 10.2% | 6.6% | 7.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 225.6% | 54.5% | 67.7% | 53.7% | 26.1% | 16.7% | 15.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 4.8% | 3.4% | 1.9% | 6.7% | 9.2% | 5.7% | 4.4% | 4.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.0% | 3.6% | 2.9% | 7.7% | 10.8% | 6.9% | 5.4% | 6.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 43.5 | 20.1 | 5.2 | 2.2 | 1.6 | 1.5 | 1.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 663,780 | 854,199 | 981,724 | 1,076,138 | 1,348,196 | 1,416,947 | 1,421,000 | 489,874 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
PHARMALITA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-03-18 | 2024-03-20 | 1713.42 |
PHARMALITA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-09-02 | 2025-09-02 | 7843.85 |
| 2025-07-28 | 2025-07-29 | 4656.73 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
PHARMALITA, UAB (code 300065321) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of EUR 5.84 million and net profit of EUR 278.8 thousand, with a profit margin of 4.8%. Revenue increased by 2.7% year on year and by 3.0% over two years, showing steady top-line growth. Profitability improved compared with 2024, when net profit was EUR 249.2 thousand, although it remained below the EUR 325.0 thousand achieved in 2023. The balance sheet expanded further in 2025: total assets reached EUR 3.91 million, equity was EUR 1.83 million, and liabilities stood at EUR 2.08 million. The equity ratio was 46.8%, while debt-to-equity was 1.14. Efficiency indicators were solid, with asset turnover at 1.49x, return on equity at 15.2%, and return on assets at 7.1%. Revenue per employee amounted to EUR 530.7 thousand, indicating relatively high productivity.